References

1. Hanna E, Wanamaker J, Adelstein D, et al. Extranodal lymphomas of the head and neck. A 20-year experience. Arch Otolaryngol Head Neck Surg 1997; 123(12):1318-1323.

2. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17(12):3835-3849.

3. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346(25):1937-1947.

4. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin' s Lymphoma Pathologic Classification Project. Cancer 1982; 49(10):2112-2135.

5. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group (see comments). Blood 1994; 84(5):1361-1392.

6. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365(9464):1054-1061.

7. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7(4):387-397.

8. Licht JD, Sternberg DW. The molecular pathology of acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2005:137-142.

9. Chamberlain MC, Nolan C, Abrey LE. Leukemic and lymphomatous meningitis: incidence, prognosis, and treatment. J Neurooncol 2005; 75(1):71-83.

10. Wang SA, Rahemtullah A, Faquin WC, et al. Hodgkin's lymphoma of the thyroid: a clinicopathologic study of five cases and review of the literature. Mod Pathol 2005; 18(12):1577-1584.

11. Ha CS, Shadle KM, Medeiros LJ, et al. Localized non-Hodgkin lymphoma involving the thyroid gland. Cancer 2001; 91(4):629-635.

12. Ansell SM, Grant CS, Habermann TM. Primary thyroid lymphoma. Semin Oncol 1999; 26(3):-316-323.

13. Pyke CM, Grant CS, Habermann TM, et al. Non-Hodgkin's lymphoma of the thyroid: is more than biopsy necessary? World J Surg 1992; 16(4):604-609; discussion 609-610.

14. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003; 21(22):4157-4164.

15. Kojima M, Tamaki Y, Nakamura S, et al. Malignant lymphoma of Waldeyer's ring. A histological and immunohistochemical study. APMIS 1993; 101(7):537-544.

16. Tan LH. Lymphomas involving Waldeyer's ring: placement, paradigms, peculiarities, pitfalls, patterns, and postulates. Ann Acad Med Singapore 2004; 33(4 suppl):15-26.

17. Zucca E, Fontana S, Roggero E, et al. Treatment and prognosis of centrocytic (mantle cell) lymphoma: a retrospective analysis of twenty-six patients treated in one institution. Leuk Lymphoma 1994; 13(1-2):105-110.

18. Quinones-Avila Mdel P, Gonzalez-Longoria AA, Admirand JH, et al. Hodgkin lymphoma involving Waldeyer's ring: a clinicopathologic study of 22 cases. Am J Clin Pathol 2005; 123(5):651-656.

19. Jaffe ES, Chan JK, Su IJ, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas; definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20(1):103-111.

20. Cheung MM, Chan JK, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998; 16(1):70-77.

21. Cuadra-Garcia I, Proulx G, Wu C, et al. Sinonasal lymphoma: a clinicopathologic analysis of 58 cases from the Massachusetts General Hospital. Am J Surg Pathol 1999; 23(11):1356-1369.

22. Oprea C, Cainap C, Azoulay R, et al. Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases. Br J Haematol 2005; 131(4):468-471.

23. Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000; 18(1):54-63.

24. Bahler DW, Swerdlow SH. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjögren's syndrome) begin as nonmalignant antigen-selected expansions. Blood 1998; 91(6): 864-1872.

25. Harris N. Lymphoid proliferations of the salivary glands. Am J Clin Pathol 1999; 111(1 suppl)1: S94-S103.

26. Hsi E, Zukerberg L, Schnitzer B, et al. Development of extrasalivary gland lymphoma in myoepithelial sialadenitis. Mod Pathol 1995; 8(8):817-824.

27. Pescarmona E, Perez M, Faraggiana T, et al. Nodal peripheral T-cell lymphoma associated with Warthin's tumour. Histopathology 2005; 47(2):221-222.

28. Chang CC, Rowe JJ, Hawkins P, et al. Mantle cell lymphoma of the hard palate: a case report and review of the differential diagnosis based on the histomorphology and immunophenotyping pattern. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 96(3):316-320.

29. Tauber S, Nerlich A, Lang S. MALT lymphoma of the paranasal sinuses and the hard palate: report of two cases and review of the literature. Eur Arch Otorhinolaryngol 2006; 263(1):19-22.

30. Coupland SE, Krause L, Delecluse HJ, et al. Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases. Ophthalmology 1998; 105(8):1430-1441.

31. Ahmed, S, Shahid RK, Sison CP, et al. Orbital lymphomas: a clinicopathologic study of a rare disease. Am J Med Sci 2006; 331(2):79-83.

32. Martinet S, Ozsahin M, Belkacemi Y, et al. Outcome and prognostic factors in orbital lymphoma: a Rare Cancer Network study on 90 consecutive patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003; 55(4):892-898.

33. Su WP, Alegre VA, White WL. Myelofibrosis discovered after diagnosis of Sweet's syndrome. Int J Dermatol 1990; 29(3):201-204.

34. Ferri E, Minotto C, Ianniello F, et al. Maxillo-ethmoidal chloroma in acute myeloid leukaemia: case report. Acta Otorhinolaryngol Ital 2005; 25(3):195-199.

35. Genet P, Pulik M, Lionnet F, et al. Leukemic relapse presenting with bronchial obstruction caused by granulocytic sarcoma. Am J Hematol 1994; 47(2):142-143.

36. Ward JH. Autoimmunity in chronic lymphocytic leukemia. Curr Treat Options Oncol 2001; 2(3): 253-257.

37. Carbone P, Kaplan H, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31(11):1860-1861.

38. Israel O, Keidar Z, Bar-Shalom R. Positron emission tomography in the evaluation of lymphoma. Semin Nucl Med 2004; 34(3):166-179.

39. Dimopoulos MA, Hamilos G. Solitary bone plasmacytoma and extramedullar plasmacytoma. Curr Treat Options Oncol 2002; 3(3):255-259.

40. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev 2004; 18(2): 115-136.

41. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy J Clin Oncol 2004; 22(8):1454-1459.

42. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17(1):268-276.

43. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16(8):2825-2833.

44. Guadagnolo BA, Li S, Neuberg D, et al. Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 2006; 64 (3):928-934.

45. Tsang RW, Gospodarowicz MK. Radiation therapy for localized low-grade non-Hodgkin's lymphomas. Hematol Oncol 2005; 23(1):10-17.

46. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346(4):235-242.

47. Hayabuchi N, Shibamoto Y, Nakamura K, et al. Stage I and II aggressive B-cell lymphomas of the head and neck: radiotherapy alone as a treatment option and the usefulness of the new prognostic index B-ALPS. Int J Radiat Oncol Biol Phys 2003; 55(1):44-50.

48. Sasai K, Yamabe H, Kokubo M, et al. Head-and-neck stages I and II extranodal non-Hodgkin's lymphomas: real classification and selection for treatment modality. Int J Radiat Oncol Biol Phys 2000; 48(1):153-160.

49. Nathu RM, Mendenhall NP, Almasri NM, et al. Non-Hodgkin' s lymphoma of the head and neck: a 30-year experience at the University of Florida. Head Neck 1999; 21(3):247-254.

50. Tham IW, Lee KM, Yap SP, et al. Outcome of patients with nasal natural killer (NK)/T-cell lymphoma treated with radiotherapy, with or without chemotherapy. Head Neck 2006; 28(2):126-134.

51. Yu KH, Yu SC, Teo PM, et al. Nasal lymphoma: results of local radiotherapy with or without chemotherapy. Head Neck 1997; 19(4):251-259.

52. Frata P, Buglione M, Grisanti S, et al. Localized extranodal lymphoma of the head and neck: retrospective analysis of a series of 107 patients from a single institution. Tumori 2005; 91(6):456-462.

53. DiBiase SJ, Grigsby PW, Guo C, et al. Outcome analysis for stage IE and IIE thyroid lymphoma. Am J Clin Oncol 2004; 27(2):178-184.

54. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin' s lymphoma. N Engl J Med 1998; 339(1):21-26; comments N Engl J Med 1998; 339(20):1475-1477.

55. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333(23):1540-1545.

56. Alexiou C, Kau RJ, Dietzfelbinger H, et al. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer 1999; 85(11):2305-2314.

57. Li Y-X, Yao B, Jin J, et al. Radiotherapy as primary treatment for sIE and IIE nasal natural killer/ T-cell lymphoma. J Clin Oncol 2006; 24(1):181-189.

58. Chim C-S, Ma S-Y, Au W-Y, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004; 103(1):216-221.

59. Hoelzer D, Gokbuget N. Treatment of lymphoblastic lymphoma in adults. Best Pract Res Clin Haematol 2002; 15(4):713-728.

60. Finazzi G, Barbui T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev 2005; 19(5):243-252.

61. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353(1):33-45.

62. Cervantes F. Modern management of myelofibrosis. Br J Haematol 2005; 128(5):583-592.

63. Rondelli D, Barosi G, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105(10):4115-4119.

64. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348(11):994-1004.

65. The International Non-Hodgkin' s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329(14):987-994; comments in N Engl J Med 1994; 330(8):574.

66. Solal-Celigny P, Roy P, Colombat P, et al. Follicular Lymphoma International Prognostic Index. Blood 2004; 104(5):1258-1265; comment in Blood 2005; 105(12):4892.

67. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100(13): 4272-4290.

68. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79(4):250-260; comments, 281-282.

69. Ferguson BJ. Mucormycosis of the nose and paranasal sinuses. Otolaryngol Clin North Am 2000; 33 (2):349-365.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment